AroCell nomination committee for the AGM 2025

AroCell AB (publ.) publishes the nomination committee’s composition for the AGM in 2025.

The nomination committee, which is appointed in accordance with the principles adopted by the annual general meeting on May 22nd, 2024, consists of:

Jon Eiken, (chairman of the nomination committee), representing his own shares
Jerker Swanstein, representing Labbex Förvaltnings AB
Greg Dingizian, representing his own shares

Before the annual general meeting 2025, the nomination committee shall prepare a proposal for the election of the chairman and other members of the board of directors, the election of the chairman of the annual meeting, the election of auditors, the determination of fees, and matters pertaining to it.

For more information, please visit:
Nomination committee - AroCell

Shareholders who wish to submit proposals to the nomination committee for the annual general meeting 2025 can e-mail info@arocell.com (header ”AroCell´s nomination committee”).

The proposals should be submitted to the nomination committee before January 31st, 2025.

About AroCell

AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, AroCell uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; www.arocell.com